{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:16:16Z","timestamp":1792088176020,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":1619,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["F4704-B20"],"award-info":[{"award-number":["F4704-B20"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["SFB F4701-B20"],"award-info":[{"award-number":["SFB F4701-B20"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","exphem.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.exphem.2017.09.012","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T22:07:50Z","timestamp":1507846070000},"page":"50-59.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia"],"prefix":"10.1016","volume":"57","author":[{"given":"Michael","family":"Willmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Sadovnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Eisenwort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Entner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Bernthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Stefanzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Hadzijusufovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"R\u00fclicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2017.09.012_bib0010","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2017.09.012_bib0015","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2017.09.012_bib0020","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.09.012_bib0025","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2017.09.012_bib0030","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.exphem.2017.09.012_bib0035","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","article-title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity","volume":"37","author":"Konopka","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2017.09.012_bib0040","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.exphem.2017.09.012_bib0045","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2017.09.012_bib0050","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.09.012_bib0055","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2017.09.012_bib0060","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2017.09.012_bib0065","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2017.09.012_bib0070","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.09.012_bib0075","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.seminhematol.2010.06.005","article-title":"Resistance to imatinib: mutations and beyond","volume":"47","author":"La Ros\u00e9e","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2017.09.012_bib0080","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.09.012_bib0085","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2141.2008.07197.x","article-title":"Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease","volume":"142","author":"Valent","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2017.09.012_bib0090","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2008.17.5745","article-title":"Chronic myeloid leukemia stem cells","volume":"26","author":"Kavalerchik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2017.09.012_bib0095","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2009-05-222471","article-title":"Properties of CD34+ CML stem\/progenitor cells that correlate with different clinical responses to imatinib mesylate","volume":"116","author":"Jiang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.09.012_bib0100","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2017.09.012_bib0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2174\/156800911793743655","article-title":"Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept","volume":"11","author":"Valent","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.exphem.2017.09.012_bib0110","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.09.012_bib0115","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood.V88.6.2162.bloodjournal8862162","article-title":"Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia","volume":"88","author":"Petzer","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.09.012_bib0120","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/sj.leu.2403649","article-title":"Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease","volume":"19","author":"Eisterer","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.09.012_bib0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10428190500272507","article-title":"Detection of molecular targets on the surface of CD34+\/CD38- stem cells in various myeloid malignancies","volume":"47","author":"Florian","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2017.09.012_bib0130","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein","volume":"107","author":"J\u00e4r\u00e5s","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2017.09.012_bib0135","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.21915","article-title":"Characterization of chronic myeloid leukemia stem cells","volume":"86","author":"Gerber","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2017.09.012_bib0140","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.09.012_bib0145","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","article-title":"Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML","volume":"129","author":"Warfvinge","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.09.012_bib0150","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.09.012_bib0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/leu.2008.246","article-title":"Targeting the leukemic stem cell: the Holy Grail of leukemia therapy","volume":"23","author":"Misaghian","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.09.012_bib0160","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2017.09.012_bib0165","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.molonc.2010.06.001","article-title":"Targeting leukemic stem cells by breaking their dormancy","volume":"4","author":"Essers","year":"2010","journal-title":"Mol Oncol"},{"key":"10.1016\/j.exphem.2017.09.012_bib0170","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/sj.leu.2401875","article-title":"Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cells","volume":"14","author":"D\u00fcrig","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.09.012_bib0175","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1634\/stemcells.20-3-259","article-title":"Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1","volume":"20","author":"Peled","year":"2002","journal-title":"Stem Cells"},{"key":"10.1016\/j.exphem.2017.09.012_bib0180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.drup.2009.06.001","article-title":"Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches","volume":"12","author":"Konopleva","year":"2009","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.exphem.2017.09.012_bib0185","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bcp.2010.04.003","article-title":"The bone marrow microenvironment as a sanctuary for minimal residual disease in CML","volume":"80","author":"Nair","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.exphem.2017.09.012_bib0190","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood-2009-01-202606","article-title":"The leukemic stem cell niche: current concepts and therapeutic opportunities","volume":"114","author":"Lane","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.09.012_bib0195","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","article-title":"Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia","volume":"21","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2017.09.012_bib0200","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.stem.2015.02.014","article-title":"Normal and leukemic stem cell niches: insights and therapeutic opportunities","volume":"16","author":"Schepers","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2017.09.012_bib0205","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-15-0767","article-title":"Identification of CD25 as STAT5-dependent growth regulator of leukemic stem cells in Ph+ CML","volume":"22","author":"Sadovnik","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2017.09.012_bib0210","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.exphem.2017.04.003","article-title":"Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: potential diagnostic value and functional implications","volume":"51","author":"Sadovnik","year":"2017","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2017.09.012_bib0215","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1126\/science.1097071","article-title":"Modulation of hematopoietic stem cell homing and engraftment by CD26","volume":"305","author":"Christopherson","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.exphem.2017.09.012_bib0220","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.exphem.2006.03.012","article-title":"G-CSF- and GM-CSF-induced upregulation of CD26 peptidase downregulates the functional chemotactic response of CD34+CD38- human cord blood hematopoietic cells","volume":"34","author":"Christopherson","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2017.09.012_bib0225","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/scd.2007.9995","article-title":"Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic\/severe combined immunodeficiency mice","volume":"16","author":"Campbell","year":"2007","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.exphem.2017.09.012_bib0230","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1185\/030079908X260925","article-title":"Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes","volume":"24","author":"Raz","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.exphem.2017.09.012_bib0235","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrd2245","article-title":"Sitagliptin","volume":"6","author":"Drucker","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.exphem.2017.09.012_bib0240","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1345\/aph.1G665","article-title":"Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"40","author":"Miller","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.exphem.2017.09.012_bib0245","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2337\/dc15-2298","article-title":"A protein preload enhances the glucose-lowering efficacy of vildagliptin in type 2 diabetes","volume":"39","author":"Wu","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.exphem.2017.09.012_bib0250","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s12020-015-0841-1","article-title":"Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes","volume":"52","author":"Bekiari","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.exphem.2017.09.012_bib0255","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-13-2811","article-title":"Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML","volume":"20","author":"Blatt","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2017.09.012_bib0260","doi-asserted-by":"crossref","first-page":"33016","DOI":"10.18632\/oncotarget.9108","article-title":"Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects","volume":"7","author":"Culen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2017.09.012_bib0265","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood.V88.10.3765.bloodjournal88103765","article-title":"Enhanced detection, maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating factor","volume":"88","author":"Hogge","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.09.012_bib0270","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.exphem.2007.01.023","article-title":"Optimizing therapy of chronic myeloid leukemia","volume":"35","author":"Deininger","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2017.09.012_bib0275","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.exphem.2016.11.005","article-title":"Preclinical approaches in chronic myeloid leukemia: from cells to systems","volume":"47","author":"Clarke","year":"2017","journal-title":"Exp Hematol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X17308160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X17308160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:30:36Z","timestamp":1668645036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X17308160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":54,"alternative-id":["S0301472X17308160"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2017.09.012","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2017.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 ISEH \u2013 Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}